Virosome studied by MedImmune

By Dylan Bushell-Embling
Friday, 18 July, 2008

Technology developed by Norwood Abbey's [ASX: NAL] second-tier subsidiary Virosome Biologicals is being evaluated by US company MedImmune.

The companies have signed a six-month exclusive evaluation agreement over Virosome's virosomal vaccine technology. In this time the companies will collaborate on research using the virosome technology with MedImmune vaccine candidates.

MedImmune is a member of the AstraZeneca group.

Proposed Australian trial eyes up blood testing for Alzheimer's

Utilising networks of GPs across three states, a large-scale study intends on combining digital...

Applications open for $300K pandemic therapeutics fellowships

Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...

CTA granted for CAR-T cell therapy for multiple myeloma

The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...

Content from other channels on our network

Calibration explained: principles, processes and modern reporting

Foodmach invests in A&RT

Ensuring reliable level measurement in tanks with internal obstructions

Siemens announces turnkey industrial edge AI solution

Biotechnology innovations in latest $6.9m industry grant funding

National Pain Alliance launched to advocate for chronic pain

Sexual misconduct findings added to public register under "landmark reforms"

Australia invests further $14.6 million in national allergy research

Can seasonal influenza vaccination prime the immune system for future strains?

"Targeted supports" launched for former patients of Simon Gordon

What can food manufacturers learn from viral food trends?

Lion 'flicks the switch' to electric at Speight's Brewery

NZ Winegrowers calls for a White Wine Emoji

Nutrition claims compliance, fresh produce guide updated

Automation and process control for new beverage canning facility